ERBB2 and breast cancer: Furthermore, additional PRs in patients with solid tumors were reported with Alisertib in combination with other drugs, such as Pazopanib against breast cancer and mesothelioma (7%, NCT01639911), Irinotecan and Temozolomide against neuroblastoma (12.5%, NCT01601535), Oxaliplatin, Leucovorin, and Fluorouracil against colorectal cancer (8.3%, NCT02319018), and Fulvestrant against lobular ER+/PR+/HER2-breast cancer (22.2%, NCT02219789) [136,137,138,139].